Literature DB >> 14730417

Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells.

C Hoffmann1, M R Leitz, S Oberdorf-Maass, M J Lohse, K-N Klotz.   

Abstract

Although many beta1-receptor antagonists and beta2-receptor agonists have been used in pharmacotherapy for many years their pharmacological properties at all three known subtypes of beta-adrenergic receptors are not always well characterized. The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of human beta-adrenergic receptors in an identical cellular background. We generated Chinese hamster ovary (CHO) cells stably expressing the three beta-adrenergic receptor subtypes at comparable levels. We characterized these receptor subtypes and analyzed the affinity of routinely used drugs as well as experimental compounds in competition binding studies, using the non-selective antagonist 125I-cyanopindolol as a radioligand. Furthermore, we analyzed the beta-receptor-mediated adenylyl cyclase activity in isolated membranes from these cell lines. The results from our experiments show that all compounds exhibit distinct patterns of selectivity and activity at the three beta-receptor subtypes. In particular, a number of beta2- or beta3-receptor agonists that are inverse agonists at the other subtypes were identified. In addition, beta1-receptor antagonists with agonistic activity at beta2- and beta3-receptors were found. These specific mixtures of agonism, antagonism, and inverse agonism at different subtypes may have important implications for the therapeutic use of the respective compounds.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14730417     DOI: 10.1007/s00210-003-0860-y

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  34 in total

Review 1.  Beta-adrenoceptor agonists and asthma--100 years of development.

Authors:  Bertil Waldeck
Journal:  Eur J Pharmacol       Date:  2002-06-07       Impact factor: 4.432

Review 2.  Molecular mechanisms of beta-adrenergic relaxation of airway smooth muscle.

Authors:  M I Kotlikoff; K E Kamm
Journal:  Annu Rev Physiol       Date:  1996       Impact factor: 19.318

3.  Molecular characterization of the human beta 3-adrenergic receptor.

Authors:  L J Emorine; S Marullo; M M Briend-Sutren; G Patey; K Tate; C Delavier-Klutchko; A D Strosberg
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

4.  Synthesis of new delta 2-isoxazoline derivatives and their pharmacological characterization as beta-adrenergic receptor antagonists.

Authors:  P Conti; C Dallanoce; M De Amici; C De Micheli; K N Klotz
Journal:  Bioorg Med Chem       Date:  1998-04       Impact factor: 3.641

5.  Negative antagonists promote an inactive conformation of the beta 2-adrenergic receptor.

Authors:  P Samama; G Pei; T Costa; S Cotecchia; R J Lefkowitz
Journal:  Mol Pharmacol       Date:  1994-03       Impact factor: 4.436

6.  Differential expression of the beta-adrenergic receptor modifies agonist stimulation of adenylyl cyclase: a quantitative evaluation.

Authors:  B S Whaley; N Yuan; L Birnbaumer; R B Clark; R Barber
Journal:  Mol Pharmacol       Date:  1994-03       Impact factor: 4.436

7.  Potent and selective human beta(3)-adrenergic receptor antagonists.

Authors:  M R Candelore; L Deng; L Tota; X M Guan; A Amend; Y Liu; R Newbold; M A Cascieri; A E Weber
Journal:  J Pharmacol Exp Ther       Date:  1999-08       Impact factor: 4.030

8.  Functional properties of the rat and human beta 3-adrenergic receptors: differential agonist activation of recombinant receptors in Chinese hamster ovary cells.

Authors:  S B Liggett
Journal:  Mol Pharmacol       Date:  1992-10       Impact factor: 4.436

9.  The affinity of (-)-propranolol for beta 1- and beta 2-adrenoceptors of human heart. Differential antagonism of the positive inotropic effects and adenylate cyclase stimulation by (-)-noradrenaline and (-)-adrenaline.

Authors:  E Gille; H Lemoine; B Ehle; A J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-10       Impact factor: 3.000

10.  Structural and conformational features determining selective signal transduction in the beta 3-adrenergic receptor.

Authors:  N Blin; L Camoin; B Maigret; A D Strosberg
Journal:  Mol Pharmacol       Date:  1993-12       Impact factor: 4.436

View more
  121 in total

1.  Pro-inflammatory responses in human monocytes are beta1-adrenergic receptor subtype dependent.

Authors:  Laurel A Grisanti; Janel Evanson; Erica Marchus; Heather Jorissen; Andrew P Woster; Wanda DeKrey; Edward R Sauter; Colin K Combs; James E Porter
Journal:  Mol Immunol       Date:  2010-01-29       Impact factor: 4.407

2.  Mechanisms of reflex bladder activation by pudendal afferents.

Authors:  John P Woock; Paul B Yoo; Warren M Grill
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-11-10       Impact factor: 3.619

3.  {Beta}-blocker drugs mediate calcium signaling in native central nervous system neurons by {beta}-arrestin-biased agonism.

Authors:  Anastassios V Tzingounis; Mark von Zastrow; Guillermo A Yudowski
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-15       Impact factor: 11.205

4.  Human atrial β(1L)-adrenoceptor but not β₃-adrenoceptor activation increases force and Ca(2+) current at physiological temperature.

Authors:  Torsten Christ; Peter Molenaar; Paul M Klenowski; Ursula Ravens; Alberto J Kaumann
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

5.  Functional investigation of β-adrenoceptors in human isolated detrusor focusing on the novel selective β3-adrenoceptor agonist KUC-7322.

Authors:  Yasuhiko Igawa; Tim Schneider; Yoshinobu Yamazaki; Satoshi Tatemichi; Yukio Homma; Osamu Nishizawa; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-05-29       Impact factor: 3.000

6.  The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.

Authors:  Jillian G Baker
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

7.  Comparison of dynamics of extracellular accesses to the β(1) and β(2) adrenoceptors binding sites uncovers the potential of kinetic basis of antagonist selectivity.

Authors:  Balaji Selvam; Jeff Wereszczynski; Irina G Tikhonova
Journal:  Chem Biol Drug Des       Date:  2012-05-02       Impact factor: 2.817

8.  Real-time optical recording of beta1-adrenergic receptor activation reveals supersensitivity of the Arg389 variant to carvedilol.

Authors:  Francesca Rochais; Jean-Pierre Vilardaga; Viacheslav O Nikolaev; Moritz Bünemann; Martin J Lohse; Stefan Engelhardt
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

9.  Cardiac implications for the use of beta2-adrenoceptor agonists for the management of muscle wasting.

Authors:  Peter Molenaar; Lu Chen; William A Parsonage
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

10.  Do β-adrenoceptor agonists induce homologous or heterologous desensitization in rat urinary bladder?

Authors:  Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-11-10       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.